CRXTQ: AI 评分 68/100 — AI 分析 (4月 2026)

Clarus Therapeutics Holdings, Inc. is a pharmaceutical company focused on oral testosterone replacement therapy, primarily JATENZO, for hypogonadal men in the United States. The company filed for Chapter 11 reorganization in September 2022 and currently trades on the OTC market.

Key Facts: AI Score: 68/100 Sector: Healthcare

公司概况

概要：

Clarus Therapeutics Holdings, Inc. is a pharmaceutical company specializing in oral testosterone replacement therapy, primarily JATENZO, targeting hypogonadal men. Facing financial challenges, the company filed for Chapter 11 reorganization and now operates on the OTC market, navigating a competitive landscape of established pharmaceutical companies.

CRXTQ是做什么的？

Founded in 2003 and based in Northbrook, Illinois, Clarus Therapeutics Holdings, Inc. is a pharmaceutical company dedicated to developing and commercializing oral testosterone replacement therapies. Its primary product, JATENZO, is a soft gel oral formulation of testosterone undecanoate designed to treat hypogonadal men. This therapy offers an alternative to traditional testosterone replacement methods, such as injections or topical gels. In addition to JATENZO, Clarus has licensing agreements with HavaH Therapeutics to develop androgen therapies for inflammatory breast disease and certain forms of breast cancer. They also have a license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. However, on September 5, 2022, Clarus Therapeutics Holdings, Inc. and its affiliate filed for Chapter 11 reorganization in the U.S. Bankruptcy Court for the District of Delaware, impacting its operational and financial stability. The company now trades on the OTC market.

CRXTQ的投资论点是什么？

Clarus Therapeutics Holdings, Inc. faces significant challenges following its Chapter 11 filing in September 2022. The company's primary asset, JATENZO, targets a specific market segment within testosterone replacement therapy. The company's gross margin stands at 80.5%. However, the company's profit margin is -404.9%. Trading on the OTC market introduces liquidity and regulatory risks. Potential investors should carefully consider the implications of the bankruptcy proceedings and the inherent risks associated with OTC-listed companies before making any investment decisions. The company's future hinges on successful restructuring and potential strategic partnerships.

CRXTQ在哪个行业运营？

Clarus Therapeutics Holdings, Inc. operates within the drug manufacturing industry, focusing on therapies for hormone replacement. The market for testosterone replacement therapy is driven by an aging population and increasing awareness of hypogonadism. However, the industry is highly competitive, with established pharmaceutical companies and generic drug manufacturers vying for market share. Clarus faces competition from companies offering alternative testosterone delivery methods, such as injections, topical gels, and patches. The company's Chapter 11 filing adds another layer of complexity in a sector characterized by stringent regulatory requirements and high research and development costs.

Drug Manufacturers - General

Healthcare

CRXTQ有哪些增长机遇？

Expansion of JATENZO Market Share: Clarus has the opportunity to increase the market share of JATENZO within the oral testosterone replacement therapy segment. This can be achieved through targeted marketing campaigns, improved patient education, and strategic partnerships with healthcare providers. The global testosterone replacement therapy market is projected to reach $2.1 billion by 2027, providing a substantial market for JATENZO to penetrate further. Timeline: Ongoing.
Development of New Androgen Therapies: The licensing agreement with HavaH Therapeutics presents an opportunity to develop novel androgen therapies for inflammatory breast disease and certain forms of breast cancer. Successful development and commercialization of these therapies could diversify Clarus's product portfolio and tap into new therapeutic areas. The market for breast cancer therapies is estimated to reach $30 billion by 2028. Timeline: 3-5 years.
Commercialization of CoQ10 Deficiency Treatment: The license agreement with McGill University to develop and commercialize technology for treating CoQ10 deficiencies offers another avenue for growth. CoQ10 deficiencies are associated with various neurological and muscular disorders, representing a significant unmet medical need. The market for CoQ10 supplements and treatments is growing, driven by increasing awareness of its health benefits. Timeline: 3-5 years.
Strategic Partnerships and Acquisitions: Clarus could pursue strategic partnerships or acquisitions to expand its product portfolio, access new markets, or enhance its research and development capabilities. Collaborations with other pharmaceutical companies or biotechnology firms could accelerate the development and commercialization of new therapies. The pharmaceutical industry is characterized by frequent mergers and acquisitions, providing opportunities for Clarus to participate in consolidation. Timeline: Ongoing.
Restructuring and Financial Turnaround: Successful restructuring under Chapter 11 could provide Clarus with a fresh start and the opportunity to streamline its operations, reduce its debt burden, and improve its financial performance. A successful turnaround could restore investor confidence and unlock the company's long-term growth potential. The timeline for restructuring is dependent on the bankruptcy court proceedings and the company's ability to negotiate with creditors. Timeline: 1-2 years.

Gross Margin of 80.5% indicates strong potential profitability on sales before operating expenses.
Filed for Chapter 11 reorganization on September 5, 2022, impacting financial stability and future operations.
Offers JATENZO, an oral testosterone replacement therapy, targeting the hypogonadal men market.
Trades on the OTC market, indicating higher risk and lower liquidity compared to major exchanges.
Profit Margin of -404.9% signals significant financial losses and operational inefficiencies.

CRXTQ提供哪些产品和服务？

Develop and commercialize oral testosterone replacement therapy.
Offer JATENZO, a soft gel oral formulation of testosterone undecanoate.
Target hypogonadal men with testosterone deficiency.
Hold licensing agreements for androgen therapies targeting inflammatory breast disease and breast cancer.
Collaborate with McGill University to develop treatments for CoQ10 deficiencies.
Operate in the pharmaceutical industry, subject to regulatory approvals and market competition.

CRXTQ如何赚钱？

Develop and obtain regulatory approval for pharmaceutical products.
Manufacture and market JATENZO for testosterone replacement therapy.
Generate revenue through sales of JATENZO.
License technology and collaborate with other companies for new product development.

Hypogonadal men diagnosed with testosterone deficiency.
Healthcare providers who prescribe testosterone replacement therapy.
Pharmacies that dispense JATENZO.
Patients seeking oral alternatives to traditional testosterone treatments.

Proprietary oral formulation of testosterone undecanoate (JATENZO).
Licensing agreements for novel androgen therapies and CoQ10 deficiency treatments.
Established presence in the testosterone replacement therapy market.
Intellectual property protection for JATENZO and other pipeline products.

什么因素可能推动CRXTQ股价上涨？

Ongoing: Restructuring efforts under Chapter 11 bankruptcy proceedings could lead to improved financial stability and operational efficiency.
Upcoming: Potential FDA approvals for new therapies developed through licensing agreements with HavaH Therapeutics and McGill University.
Ongoing: Strategic partnerships or acquisitions to expand the product portfolio and market reach.

CRXTQ的主要风险是什么？

Ongoing: Chapter 11 bankruptcy proceedings create uncertainty about the company's future viability.
Potential: Competition from established pharmaceutical companies and generic drug manufacturers.
Potential: Regulatory challenges and potential changes in guidelines for testosterone replacement therapy.
Ongoing: Limited financial disclosure and transparency due to OTC listing.
Potential: Low trading volume and liquidity on the OTC market.

CRXTQ的核心优势是什么？

Proprietary oral formulation of testosterone (JATENZO).
Licensing agreements for potential new therapies.
Established presence in the testosterone replacement market.
Gross margin of 80.5%.

CRXTQ的劣势是什么？

Chapter 11 bankruptcy filing.
Negative profit margin (-404.9%).
Limited product portfolio concentrated on JATENZO.
Trading on the OTC market with associated risks.

CRXTQ有哪些机遇？

Expansion of JATENZO market share.
Development and commercialization of new androgen therapies.
Commercialization of CoQ10 deficiency treatment.
Strategic partnerships and acquisitions.

CRXTQ面临哪些威胁？

Competition from established pharmaceutical companies.
Regulatory challenges and potential changes in guidelines.
Generic competition for JATENZO.
Economic downturn impacting healthcare spending.

CRXTQ的竞争对手是谁？

Aleafia Health Inc. — Cannabis products and services. — (ALEAF)
Endo International plc — Generic and branded pharmaceuticals. — (ENDP)
HealthCare Capital Corp. — Specialty finance company focused on healthcare. — (HCLC)
Invitae Corporation — Genetic testing company. — (NVTAQ)
NextNav Inc. — Provides geolocation services. — (NXNN)

Key Metrics

MoonshotScore: 68/100

Company Profile

CEO: Robert E. Dudley
Headquarters: Northbrook, US
Employees: 16
Founded: 2021

AI Insight

AI analysis pending for CRXTQ

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Clarus Therapeutics Holdings, Inc. do?

Clarus Therapeutics Holdings, Inc. is a pharmaceutical company focused on the development and commercialization of oral testosterone replacement therapy. Its primary product, JATENZO, is designed to treat hypogonadal men. The company also has licensing agreements to develop therapies for inflammatory breast disease, breast cancer, and CoQ10 deficiencies. However, Clarus filed for Chapter 11 reorganization in September 2022 and now trades on the OTC market, indicating significant financial challenges.

What do analysts say about CRXTQ stock?

Given Clarus Therapeutics Holdings, Inc.'s Chapter 11 filing and OTC listing, formal analyst coverage is likely limited. Investors should focus on the company's restructuring progress, potential for new product development, and ability to navigate the bankruptcy process. Key valuation metrics are difficult to assess due to the company's financial distress. Investors should conduct thorough due diligence and consider the high risks associated with investing in distressed companies.

What are the main risks for CRXTQ?

The primary risks for Clarus Therapeutics Holdings, Inc. include the uncertainty surrounding its Chapter 11 bankruptcy proceedings, limited financial disclosure due to its OTC listing, and low trading volume and liquidity. Competition from established pharmaceutical companies and potential regulatory changes also pose risks. Investors should carefully consider these factors and the potential for significant losses before investing in CRXTQ.